

ROYCE®

KHALTATE CALCIUM LACTATE 300MG TABLET

Presentation:

White colour, round, shallow biconvex and film-coated tablet with plain on both sides; diameter: 10.33mm.

Content:

Each film-coated tablet contains:

Calcium Lactate Pentahydrate 300mg providing Calcium 40mg.

Indication:

As a health supplement.

Dosage and Administration:

To be taken with food.

Adults : 5 tablets 3 times daily or as directed by pharmacist or doctor.

Contraindication:

Unknown.

Warning and Precautions:

It should be given cautiously to patients with impaired renal function, cardiac disease, or sarcoidosis.

Interactions With Other Medicaments:

Calcium lactate must be used with care in patients receiving alternative compound vitamin or mineral preparations, which often contain additional sources of calcium.

Calcium enhances the effects of digitalis on the heart and may precipitate digitalis intoxication.

Calcium salts reduce the absorption of tetracyclines.

Side Effects:

Calcium salts can cause gastrointestinal irritation and constipation. Excessive amounts may lead to hypercalcaemia. The deposition of calcium in the kidneys leads to loss of renal concentrating capacity and renal damage. This may be reversible if treated early but uraemia and death have occurred.

Elevated serum-calcium concentrations can produce bradycardia and cardiac arrhythmias. Calcium enhances the effects of digitalis glycosides on the heart and may precipitate digitalis intoxication.

Symptoms & Treatment of Overdose:

Overdose may lead to hypercalcemia; symptoms include anorexia, lassitude, muscle and joints pains, nausea and vomiting, thirst and polyuria.

Initial management of hypercalcaemia should include rehydration by either oral or intravenous route. Intravenous rehydration may be given with or followed by, frusemide or other loop diuretics to increase calcium excretion; thiazide diuretics should be avoided as they may increase the renal reabsorption of calcium.

Other drugs which may be used if this treatment proves unsuccessful include calcitonins, the bisphosphonates, and plicamycin. Phosphates may be useful, but should be given by mouth and only to patients with low serum-phosphate concentrations and normal renal function. Haemodialysis may be considered as a last reason. Careful monitoring of serum-electrolyte concentrations is essential throughout therapy.

Storage Condition:

Keep container tightly closed. Store in a dry place (below 30°C). Protect from light.

Pack Size:

Plastic bottle of 30 tablets.
Blister packs of 3 x 10's and 10 x 10's.

Product Registration Number:

MAL13125062N

Further information can be obtained from your doctor or pharmacist.

The logo for ROYCE, featuring the word "ROYCE" in a bold, white, serif font with a registered trademark symbol (®) to its upper right, set against a solid black rectangular background.

Product Holder/Manufactured by:

ROYCE PHARMA MFG.SDN.BHD. (650435-X)

PT 1663, Nilai Industrial Estate,
71800 Nilai, Negeri Sembilan, Malaysia.

Revision date: 170516